Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327750 | 0.81 | GABRA1 (0.38) | — | |
| SCHEMBL2435652 | 0.80 | MGAM (0.40) | POLBJAK2JAK3RAB9ANPC1 | |
| SCHEMBL2432159 | 0.79 | NPC1 (0.37) | MAPTALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2433761 | 0.78 | CDK5 (0.38) | MAPTALDH1A1HSD17B10SMN1; SMN2CYP3A4 | |
| SCHEMBL2430527 | 0.77 | PDE5A (0.40) | MAPTALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2521643 | 0.76 | CCNE1 (0.35) | MAPTALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2427556 | 0.74 | KMT2A (0.39) | MAPTALDH1A1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL2430337 | 0.73 | PDE5A (0.40) | ALDH1A1HSD17B10KMT2ASMN1; SMN2JAK2 | |
| SCHEMBL2430551 | 0.73 | BRDT (0.39) | ALDH1A1HSD17B10KITCYP3A4KDM4E | |
| SCHEMBL2522289 | 0.72 | PDE5A (0.42) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010064701-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | 大塚製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | MAPT 1036/4885ALDH1A1 568/4885HSD17B10 762/4885 |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | MAPT 1036/4885ALDH1A1 568/4885HSD17B10 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.